DrugMax Management to Present at Roth Capital Partners 18th Annual Growth Stock Conference on Tuesday, February 21, 2006

FARMINGTON, Conn., Feb. 17 /PRNewswire-FirstCall/ -- DrugMax, Inc. , a specialty pharmacy and drug distribution company, today announced that Chairman & Chief Executive Officer, Ed Mercadante, and Chief Financial Officer, James Searson, are scheduled to present at the Roth Capital Partners 18th Annual Growth Stock Conference on Tuesday, February 21, 2006 at 8:00 a.m. (P.S.T.). The conference will be held at the St. Regis Monarch Beach Resort & Spa in Dana Point, CA.

Investors can access a live webcast of the presentation on the Company's Web site at http://www.drugmax.com/. A link to the webcast will be available in the Investor Relations section of the site. Please register ten minutes prior to its start. An archive of this presentation will be available for ninety days.

About DrugMax, Inc.

DrugMax, Inc. is a specialty pharmacy and drug distribution provider. DrugMax works closely with doctors, patients, managed care providers, medical centers and employers to improve patient outcomes while delivering low cost and effective healthcare solutions. The Company is focused on building an integrated specialty drug platform through its pharmacy and specialty pharmaceutical operations. DrugMax operates 84 locations, including 7 franchised locations, in 13 states under the Arrow Pharmacy & Nutrition Center and Familymeds Pharmacy brand names. The Company also operates Worksite Pharmacies(SM) located on-site at major employer groups as well as specialty pharmaceutical distribution directly to physicians and other healthcare providers. The DrugMax platform is designed to provide services for the treatment of acute and complex health diseases including chronic medical conditions such as cancer, diabetes and pain management. The Company often serves defined population groups on an exclusive, closed panel basis to maintain costs and improve patient outcomes. DrugMax offers a comprehensive selection of brand name and generic pharmaceuticals, non-prescription healthcare-related products, and diagnostic supplies to its patients, physicians, clinics, long- term care and assisted living centers. More information about DrugMax can be found at http://www.drugmax.com/. The Company's online product offering can be found at http://www.familymeds.com/.

Safe Harbor Provisions

Certain oral statements made by management from time to time and certain statements contained in press releases and periodic reports issued by DrugMax, Inc., including those contained herein, that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements, are statements regarding the intent, belief or current expectations, estimates or projections of DrugMax, its directors or its officers about DrugMax and the industry in which it operates, and include among other items, statements regarding its strategy of building an integrated specialty pharmacy platform with multiple sales channels and its growth strategies and opportunities, including its plans to provide pharmacy benefit administration services to employers and build business in its retail specialty pharmacies. When used in this report, the words "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are generally intended to identify forward-looking statements.

Important factors that could cause the actual results to differ materially from those in the forward-looking statements include, among other items, management's ability to successfully implement is business and growth strategies, including its ability to provide pharmacy benefit administration services to employers and build business in its retail specialty pharmacies. Further information relating to factors that could cause actual results to differ from those anticipated is included under the heading Risk Factors in DrugMax's Form 10-K for the year ended January 1, 2005 filed with the U.S. Securities and Exchange Commission. DrugMax disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, contact: DrugMax, Inc. Cindy Berenson, 860-676-1222 x138

First Call Analyst:
FCMN Contact: [e-mail]